1D09C3

Drug Profile

1D09C3

Alternative Names: Monoclonal antibody 1D09C3

Latest Information Update: 28 Jun 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MorphoSys
  • Developer GPC Biotech AG
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies

Highest Development Phases

  • Discontinued Haematological malignancies

Most Recent Events

  • 30 Aug 2007 GPC Biotech is slowing down certain ongoing activities and will not make further commitments to its 1D09C3 antibody programme; development is suspended until further resources are available
  • 03 Jan 2007 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006) added to the adverse events and Cancer therapeutic trials section
  • 17 Feb 2006 1D09C3 receives orphan drug status for multiple myeloma in the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top